Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2

<p>Abstract</p> <p>Background</p> <p>The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy, significantly improves survival of women with resected, HER2-overexpressing breast cancers, but is associated with toxicities including a risk of cardiomyopa...

Full description

Bibliographic Details
Main Authors: Anders Carey, Blackwell Kimberly L, Marcom Paul, Niedzwiecki Donna, Osada Takuya, Hobeika Amy, Morse Michael A, Devi Gayathri R, Lyerly H Kim, Clay Timothy M
Format: Article
Language:English
Published: BMC 2007-09-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/5/1/42

Internet

http://www.translational-medicine.com/content/5/1/42

Similar Items